Posted on 02/06/2010 in Pharmaceutical Company Product News Ferring has underlined the safety and efficacy of its Firmagon hormone treatment for prostate cancer with results from a new extension study.
The extension trial, which was designed to monitor the drug's effects beyond the original one-year timeframe of a pivotal study comparing Firmagon and leuprolide, showed that the treatment continued to be effective and well-tolerated.
In addition, it was also found that those who switched to Firmagon having been using leuprolide during the main study experienced improvements to their health.
Dr E David Crawford, head of urologic oncology at the University of Colorado, Denver Health Sciences Center and practice director for the Urologic Oncology Clinic, said the results demonstrated the benefits of staying on Firmagon.
He added: "Firmagon provides a fast and sustained reduction in testosterone levels and this new data indicate that efficacy is maintained over the long-term without any additional negative effects on tolerability."
Last month, Ferring agreed a deal to purchase the rights to the cyclic heavy menstrual bleeding drug Lysteda from Xanodyne, with an eye towards releasing the product internationally.Other news stories from 02/06/2010
Read more in the Zenopa News Archive
How this news is generated
|
